Biofrontera Inc. is a biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on the fields of photodynamic therapy and topical antibiotics. The Company's licensed products focus on the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Biofrontera Inc. is based in WOBURN, MA.
| Revenue (Most Recent Fiscal Year) | $37.32M |
| Net Income (Most Recent Fiscal Year) | $-17.76M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.15 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 12.29 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -30.28% |
| Net Margin (Trailing 12 Months) | -30.33% |
| Return on Equity (Trailing 12 Months) | -305.13% |
| Return on Assets (Trailing 12 Months) | -82.67% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.40 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.80 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 8.99 |
| Inventory Turnover (Trailing 12 Months) | 3.00 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.05 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.47 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.40 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 9.45M |
| Free Float | 9.33M |
| Market Capitalization | $5.76M |
| Average Volume (Last 20 Days) | 0.17M |
| Beta (Past 60 Months) | 0.37 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 10.08% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |